Taysha Gene Therapies, Inc.TSHANASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank17
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-1118.93%
↑ 15% vs avg
Percentile
P17
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-1319.90%
Historical baseline
PeriodValueYoY Change
2025-1118.93%-6.0%
2024-1055.45%-55.0%
2023-680.84%+89.3%
2022-6384.05%-
20210.00%-
20200.00%-
20190.00%-